✦ LIBER ✦

Possible association between Budd-Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia

✍ Scribed by Mevlüt Kurt; Ali Shorbagi; Kadri Altundag; Tamer Elkiran; Ibrahim Güllü; Emin Kansu

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 86 KB
Volume: 80
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.20432

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Gemtuzumab ozogamicin (GO; CMA‐676; Mylotarg™) is a chemotherapeutic agent approved for the treatment of CD33‐positive acute myelogenous leukemia in patients of age 60 years or older after first relapse. Hepatic veno‐occlusive disease has been reported to develop as a late complication of gemtuzumab ozogamicin treatment. A patient who developed Budd‐Chiari Syndrome with hepatic vein thrombosis following treatment with GO is presented. This complication has not been previously reported, and it deserves to be considered as a possible adverse effect of gemtuzumab ozogamicin. Am. J. Hematol. 80:213–215, 2005. © 2005 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Sequence of administration and methylati

Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML)

✍ Iris Middeldorf; Oliver Galm; Rainhardt Osieka; Edgar Jost; James G. Herman; Ste 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB 👁 2 views

Fractionated doses of gemtuzumab ozogami

Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50–70-year old: A phase 1/2 study of the acute leukemia French association

✍ Hassan Farhat; Oumedaly Reman; Emmanuel Raffoux; Celine Berthon; Cécile Pautas; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views

Reciprocal Relationship Between a Ph-Neg

Reciprocal Relationship Between a Ph-Negative Clone With Trisomy 8 Associated With Severe Myelodysplasia and a Ph-Positive Clone Following Imatinib Treatment in a Patient With Accelerated-Phase Chronic Myelogenous Leukemia (CML)

✍ Paulina Patchenko; Abraham Klepfish; Luba Trakhtenbrot; Rachel Rothman; Eliezer 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 2 views

## Cytarabine-Induced Neurotoxicity Responding to Methyl Prednisolone To the Editor: Neurotoxicity is a well-recognized complication following high-dose cytosine arabinoside (HIDAC). The pathophysiology of this toxicity is unknown, although an immune-mediated mechanism is hypothesized. We describe